{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:52:16Z","timestamp":1793407936098,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-026-04553-w","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:35:58Z","timestamp":1785357358000},"page":"2072-2083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-Specific-Activity Resin Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Study of Efficacy, Safety, and Dosimetry Considerations"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-7459","authenticated-orcid":false,"given":"Alexander","family":"Villalobos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alfrasiabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneyeh","family":"Shahbazian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes L.","family":"Du Pisanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Kokabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"4553_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.10.062","author":"A Riaz","year":"2011","unstructured":"Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.062.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4553_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27057","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014. https:\/\/doi.org\/10.1002\/hep.27057.","journal-title":"Hepatology"},{"key":"4553_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31819","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, et al. Yttrium\u201090 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021. https:\/\/doi.org\/10.1002\/hep.31819.","journal-title":"Hepatology"},{"key":"4553_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00091-7","author":"E Kim","year":"2022","unstructured":"Kim E, Sher A, Abboud G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022. https:\/\/doi.org\/10.1016\/S2468-1253(22)00091-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4553_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2023.02.030","author":"A Villalobos","year":"2023","unstructured":"Villalobos A, Arndt L, Cheng B, et al. Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: a comparative study of the effectiveness, safety, and dosimetry of glass-based versus resin-based microspheres. J Vasc Int Radiol. 2023. https:\/\/doi.org\/10.1016\/j.jvir.2023.02.030.","journal-title":"J Vasc Int Radiol."},{"key":"4553_CR6","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231386","author":"A Sarwar","year":"2024","unstructured":"Sarwar A, Malik MS, Vo NH, et al. Efficacy and safety of radiation segmentectomy with 90y resin microspheres for hepatocellular carcinoma. Radiology. 2024. https:\/\/doi.org\/10.1148\/radiol.231386.","journal-title":"Radiology."},{"key":"4553_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-025-04130-7","author":"AD Talenfeld","year":"2025","unstructured":"Talenfeld AD, Peng R, McKenney AS, et al. Segmental yttrium-90 radioembolization with day-of-calibration resin microspheres: durable transarterial ablation for solitary hepatocellular carcinoma. CardioVasc Intervent Radiol. 2025. https:\/\/doi.org\/10.1007\/s00270-025-04130-7.","journal-title":"CardioVasc Intervent Radiol"},{"key":"4553_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005198","author":"N Kokabi","year":"2022","unstructured":"Kokabi N, Webster LA, Dabbous H, et al. Resin-based 90Y tumor dose as a predictor of duration of response and survival in patients with surgically unresectable hepatocellular carcinoma: a prospective single-arm study. Clin Nucl Med. 2022. https:\/\/doi.org\/10.1097\/RLU.0000000000005198.","journal-title":"Clin Nucl Med"},{"key":"4553_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07179-1","author":"SA Montazeri","year":"2025","unstructured":"Montazeri SA, De la Garza-Ramos C, Silver C, et al. Achieving complete pathologic necrosis in hepatocellular carcinoma treated with radiation segmentectomy before liver transplantation: a comprehensive glass microsphere analysis. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07179-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4553_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06111-9","author":"N Kokabi","year":"2023","unstructured":"Kokabi N, Arndt-Webster L, Chen B, et al. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/s00259-023-06111-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4553_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2025.06.008","author":"JPTLD Alc\u00e2ntara","year":"2025","unstructured":"Alc\u00e2ntara JPTLD, Rosa G\u00f6tz GWXD. Transarterial Radioembolization with Yttrium-90 and SIRT versus conventional transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Acad Radiol. 2025. https:\/\/doi.org\/10.1016\/j.acra.2025.06.008.","journal-title":"Acad. Radiol."},{"key":"4553_CR12","unstructured":"SERVICES USDOHAH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017."},{"key":"4553_CR13","doi-asserted-by":"publisher","unstructured":"Yttrium-90 radioembolization dosimetry: dose considerations, optimization, and tips - PubMed. Seminars in interventional radiology. 03\/14\/2024;41(1)https:\/\/doi.org\/10.1055\/s-0044-1779715","DOI":"10.1055\/s-0044-1779715"},{"key":"4553_CR14","doi-asserted-by":"publisher","unstructured":"Villalobos A, Du Pisanie J, Gandhi R, Kokabi N. Yttrium-90 radioembolization dosimetry: dose considerations, optimization, and tips - PubMed. Seminars in interventional radiology. 03\/14\/2024;41(1)https:\/\/doi.org\/10.1055\/s-0044-1779715","DOI":"10.1055\/s-0044-1779715"},{"key":"4553_CR15","unstructured":"SIRTEX. Resin Microsphere Decay Charts for 3 mL and 5 mL. Accessed September 1, 2025, https:\/\/www.sirtex.com\/us\/products\/sir-spheres\/sir-spheres-y-90-resin-microspheres\/resources\/"},{"key":"4553_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07471-0","author":"A Sarwar","year":"2025","unstructured":"Sarwar A, Nasser I, Weinstein JL, et al. Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheres. Eur J Nucle Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07471-0.","journal-title":"Eur J Nucle Med Mol Imaging"},{"key":"4553_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2016.08.003","author":"MA Westcott","year":"2016","unstructured":"Westcott MA, Coldwell DM, Liu DM, Zikria JF. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol. 2016. https:\/\/doi.org\/10.1016\/j.adro.2016.08.003.","journal-title":"Adv Radiat Oncol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04553-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-026-04553-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04553-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:00:24Z","timestamp":1791320424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-026-04553-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4553"],"URL":"https:\/\/doi.org\/10.1007\/s00270-026-04553-w","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kokabi is a consultant for SIRTeX Medical, Boston Scientific, Okami Medical, Terumo Medical,\u00a0and Trisalus Life Sciences. Dr. Villalobos is a consultant for SIRTeX Medical and Guerbett. Dr. Moon is a consultant for Intercept Pharmaceuticals, AstraZeneca, Eisai and IDEOlogy\u00a0- and receives research funding (to institution) from DCN Diagnostics and Madrigal Pharmaceuticals. Dr. Du Pisanie is a consultant for Okami Medical. The remaining authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}